PACAP38
- Generic Name
- PACAP38
- Drug Type
- Biotech
- Unique Ingredient Identifier
- LK78T72MLT
Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 38
- Registration Number
- NCT05635604
- Locations
- 🇩🇰
Danish headache center, Glostrup, Denmark
The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 22
- Registration Number
- NCT04960657
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Capital Region, Denmark
The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Song Guo
- Target Recruit Count
- 20
- Registration Number
- NCT02364453
- Locations
- 🇩🇰
Danish Headache Center & Department of Neurology, Copenhagen, Glostrup, Denmark
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
Not Applicable
Completed
- Conditions
- Migraine Without Aura
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2008-05-30
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 12
- Registration Number
- NCT00380263
- Locations
- 🇩🇰
Dansih Headache Center, Glostrup, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath